VELDONA® interferon-alpha formulation has proven potential as a remedy candidate for feline persistent gingivostomatitis and canine atopic dermatitis
Ainos advances its product pipeline because it targets commencing medical research through the second quarter of 2023
SAN DIEGO, Nov 21, 2022 /PRNewswire/ — Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos”, or the “Firm”), a diversified medtech firm centered on the event of novel point-of-care testing, low-dose interferon therapeutics , and artificial RNA-driven preventive medication, in the present day introduced that it has printed preclinical knowledge demonstrating the potential of its low-dose oral interferon-alpha (IFNα) formulation, VELDONA®, as remedy candidates for the 2 commonest medical situations for canine and cats. The preclinical knowledge could be accessed right here.
Ainos intends to start medical research to evaluate VELDONA®‘s potential use within the remedy of feline persistent gingivostomatitis (FCGS) and canine atopic dermatitis (CAD) through the second quarter of 2023. The Firm initially utilized VELDONA® to feline coronavirus (FCoV)-infected fcwf-4 (feline microphage) programs to find out efficiency and dose translation. In line with the outcomes, the EC50 worth of VELDONA® was 1062 IU/mL (5.29×10-3 ng/mL). Based mostly on VELDONA®‘s efficient antiviral efficacy, the Firm is planning an enlargement of its use for the remedy of people to remedy of animals. Ainos is designing dose-finding subject research to establish optimum VELDONA® Dose through oromucosal administration for feline FCGS and canine CAD.
A report compiled by Analysis and Markets and printed by Mordor Intelligence exhibits that the worldwide pet dental well being market is projected to develop at a CAGR of 6.2%, reaching $9.98 billion by 2030. The canine market phase accounted for the biggest income share at over 55.0%, and the cat market phase is anticipated to broaden at a CAGR of 6.9%. It’s also reported that the worldwide CAD market dimension is projected to develop at a CAGR of 12.6% to succeed in $221.20 billion by 2027.
FCGS is a extreme oral mucosal inflammatory illness afflicting cats, whereas CAD is an inflammatory pores and skin illness present in canine. Each of those illnesses are widespread, tough to diagnose, and have advanced multifactorial etiologies, with advanced causes together with environmental elements, bacterial or viral infections, and aberrant host immune programs. As soon as contaminated, the host animal will show an inappropriate immune response which can require life-long treatment to manage.
Estimates of the prevalence of FCGS amongst cats vary from 0.7% to 12% and the prevalence of CAD amongst canine is estimated to be between 3% and 15%. The estimated possession of cats and canine within the US numbers 85.5 million and 78 million respectively, suggesting as much as 10.3 million cats undergo from FCGS and as much as 11.7 million canine undergo from CAD. The speed of companion animal possession within the US continues to extend, particularly amongst younger individuals. Roughly 44% of all US households have a canine and 35% of US households have a cat.
Presently, medical administration of FCGS and CAD stays extremely numerous, and is commonly dependent upon comorbidities in particular person circumstances. Typically, current pharmacotherapies for FCGS and CAD embrace antibiotics, antihistamines, and immunosuppressive brokers resembling corticosteroids or cyclosporine, which are sometimes the primary line of remedy for stricken animals. Nonetheless, the long-term adversarial results of those immunosuppressive brokers are critical, and embrace sort II diabetes and opportunistic infections. At current, no treatment exists for animals that aren’t aware of anti-inflammatory or immunosuppressive therapies, and there’s no splendid long-term answer out there to pet homeowners.
Over the course of a number of years, the Firm’s VELDONA® formulation exhibited systemic results in mice, cats, canine, rats, guinea pigs, horses, cattle, and swine, involving such indications as feed effectivity in swine and deadly virus an infection in different species (eg, canine parvovirus, horse herpes virus, and feline coronavirus). These in vivo research point out that VELDONA® can have a therapeutic or prophylactic impact at websites distal to the oral mucosa. VELDONA® modulates systemic and mucosal immunity within the absence of significant adversarial results, first-pass impact and proteolytic degradation related to different administration routes.
Chun-Hsien Tsai, Ainos’ Chairman of the Board, President, and Chief Government Officer commented, “Following our acceleration of 5 VELDONA® Candidates for Part 3 trials and commercialization, this preclinical knowledge signifies the formulation’s promising potential for an array of purposes. It additionally demonstrates that we’re efficiently executing on our technique to broaden VELDONA®‘s market, and our progress in advancing the monetization of our modern product pipeline. An increasing number of individuals are taking to pet possession, and it has change into all an important that pet homeowners have entry to protected and efficient options for his or her animals’ medical points. As we look forward to the method of conducting medical trials to evaluate VELDONA®‘s potential use within the remedy of FCGS and CAD, we’re proud to have the ability to supply a possible remedy for 2 situations that mixed have an effect on hundreds of thousands of creatures.”
About Ainos, Inc.
Headquartered in San Diego, California, Ainos, Inc. (f/ok/a Amarillo Biosciences, Inc.) is a diversified medtech firm engaged in growing modern medical applied sciences for point-of-care testing and protected and novel medical remedy for a broad vary of illness indications. Along with its proprietary therapeutics utilizing low-dose non-injectable interferon, Ainos is dedicated to growing a complete healthcare enterprise portfolio encompassing medical gadgets and shopper healthcare merchandise. Whereas prioritizing the commercialization of medical gadgets as a part of its diversification technique, Ainos has additionally expanded its product portfolio to incorporate Unstable Natural Compounds (VOC) and COVID-19 POCTs. Leveraging its patents associated to VOC applied sciences and COVID-19 POCT merchandise, the Firm seeks to expedite the commercialization of its medical system pipeline, starting with Ainos-branded COVID-19 POCT product candidates.
This press launch comprises “forward-looking statements” about Ainos inside the which means of the protected harbor provisions of the US Personal Securities Litigation Reform Act of 1995. Ahead-looking statements could be recognized by way of phrases resembling “anticipate,” ” consider,” “estimate,” “anticipate,” “intend,” “plan,” “predict,” “challenge,” “goal,” “future,” “seemingly,” “technique,” “foresee,” “could, ” “steerage,” “potential,” “outlook,” “forecast,” “ought to,” “will” or different related phrases or phrases. Equally, statements that describe the Firm’s goals, plans or targets are, or could also be, forward-looking statements. Ahead-looking statements are based mostly solely on the Firm’s present beliefs, expectations, and assumptions. Ahead-looking statements are topic to inherent uncertainties, dangers, and modifications in circumstances which can be tough to foretell and plenty of of that are exterior of the Firm’s management. The Firm’s precise outcomes could differ materially from these indicated within the forward-looking statements.
Necessary elements that might trigger the Firm’s precise outcomes to vary materially from the projections, forecasts, estimates and expectations mentioned on this press launch embrace, amongst others, the price of manufacturing and gross sales potential of the deliberate drug therapies introduced on this press launch; the Firm’s dependency on revenues from the sale of COVID-19 check kits; the Firm’s restricted money and historical past of losses; the Firm’s capability to attain profitability; the Firm’s capability to boost extra capital to proceed the Firm’s product improvement; the flexibility to precisely predict the longer term working outcomes of the Firm; the flexibility to advance Ainos’ present or future product candidates by means of medical trials, receive advertising and marketing approval and finally commercialize any product candidates the Firm develops; the flexibility to acquire and keep regulatory approval of Ainos product candidates; delays in finishing the event and commercialization of the Firm’s present and future product candidates, which may end in elevated prices to the Firm, delay or restrict the flexibility to generate income and adversely have an effect on the enterprise, monetary situation, outcomes of operations and prospects of the Firm; intense competitors and quickly advancing expertise within the Firm’s business which will outpace its expertise; buyer demand for the services and products the Firm develops; the affect of aggressive or different merchandise, applied sciences and pricing; disruption in analysis and improvement services; lawsuits and different claims by third events or investigations by varied regulatory companies governing the Firm’s operations; potential cybersecurity assaults; elevated necessities and prices associated to cybersecurity; the Firm’s capability to understand the advantages of third get together licensing agreements; the Firm’s capability to acquire and keep mental property safety for Ainos product candidates; compliance with relevant legal guidelines, rules and tariffs; and the Firm’s success in managing the expansion. A extra full description of those threat elements and others is included within the “Danger Elements” part of Ainos’ most up-to-date Annual Report on Type 10-Ok/A and different experiences filed with the US Securities and Change Fee, lots of which dangers are past the Firm’s management. Along with the dangers described above and within the Firm’s Type 10-Ok/A, different unknown or unpredictable elements additionally may trigger precise outcomes to vary materially from the projections, forecasts, estimates and expectations mentioned on this press launch.
The forward-looking statements made on this press launch are expressly certified of their entirety by the foregoing cautionary statements. Ainos undertakes no obligation to, and expressly disclaims any such obligation to, publicly replace or revise any forward-looking assertion to replicate modified assumptions, the prevalence of anticipated or unanticipated occasions or modifications to the longer term outcomes over time or in any other case, besides as required by legislation.
Investor Relations Contact
Cellphone: +1 646-224-6971
Electronic mail: Ainos.IR@icrinc.com
View unique content material: https://www.prnewswire.com/news-releases/ainos-publishes-preclinical-data-demonstrating-its-veldona-formulations-potential-as-treatment-candidates-for-the-most-common- medical-conditions-for-companion-animals-301683658.html
SOURCE Ainos, Inc.